Austar Lifesciences Limited
AULSF
$0.07
$0.0651,300.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 55.57M | 55.84M | 48.40M | 48.82M | 58.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.57M | 55.84M | 48.40M | 48.82M | 58.47M |
| Cost of Revenue | 44.74M | 44.96M | 38.36M | 38.69M | 48.14M |
| Gross Profit | 10.83M | 10.88M | 10.04M | 10.13M | 10.33M |
| SG&A Expenses | 8.76M | 8.80M | 7.79M | 7.86M | 10.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.06M | -1.07M | -739.30K | -745.80K | -344.90K |
| Total Operating Expenses | 54.53M | 54.79M | 47.03M | 47.44M | 60.48M |
| Operating Income | 1.04M | 1.04M | 1.37M | 1.38M | -2.01M |
| Income Before Tax | 833.10K | 837.10K | 634.30K | 639.80K | -1.94M |
| Income Tax Expenses | 180.90K | 181.80K | 345.00K | 348.00K | -108.00K |
| Earnings from Continuing Operations | 652.20K | 655.30K | 289.20K | 291.70K | -1.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -3.34M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 56.90K | 57.20K | 116.60K | 117.60K | 85.00K |
| Net Income | 709.10K | 712.50K | 405.80K | 409.30K | -5.09M |
| EBIT | 1.04M | 1.04M | 1.37M | 1.38M | -2.01M |
| EBITDA | 2.18M | 2.19M | 2.33M | 2.35M | -1.05M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M |
| Average Diluted Shares Outstanding | 512.58M | 512.58M | 512.58M | 512.58M | 512.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |